(238 days)
No
The summary describes a device for delivering and monitoring nitric oxide therapy with standard monitoring and delivery functions. There is no mention of AI or ML in the device description, intended use, or performance studies. The "intelligent delivery mode" is not described in a way that suggests AI/ML, and the software changes mentioned are related to alarm management and language options, not AI/ML capabilities.
Yes
The device is intended for the "delivery and monitoring of a constant (user set) concentration of nitric oxide (NO)" for "nitric oxide therapy (iNO)", which is a form of medical treatment.
No
The device is described as a "Nitric Oxide Delivery System" that "delivers and monitors a constant (user set) concentration of nitric oxide (NO) and the monitoring of NO2 and O2 in the inspiratory ventilator lines". Its primary function is to administer therapy (inhaled nitric oxide) and monitor aspects related to that therapy, not to identify or determine the nature of a disease or condition.
No
The device description explicitly lists multiple hardware components including a head unit, sample line, feed hoses, regulators, test circuit, monitors, power supply, and syringe. While there are software changes mentioned in the submission, the device itself is a system with significant hardware components.
Based on the provided text, the NOxBOXi Nitric Oxide Delivery System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Definition of IVD: An IVD device is used to examine specimens derived from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- NOxBOXi's Function: The NOxBOXi delivers and monitors gases (nitric oxide, oxygen, nitrogen dioxide) directly to a patient's inspiratory ventilator line. It is a therapeutic and monitoring device used in vivo (within the living body), not in vitro (in a test tube or lab setting).
- Intended Use: The intended use clearly states it's for "delivery and monitoring of a constant (user set) concentration of nitric oxide... in the inspiratory ventilator lines of a patient undergoing nitric oxide therapy." This is a direct patient treatment and monitoring function.
- Device Description: The description reinforces its role in delivering and monitoring gases in the ventilator circuit connected to a patient.
Therefore, the NOxBOXi Nitric Oxide Delivery System is a therapeutic and monitoring medical device, not an IVD.
N/A
Intended Use / Indications for Use
NOxBOXi Nitric Oxide Delivery System is intended for use by healthcare professionals for the delivery and monitoring of a constant (user set) concentration of nitric oxide (NO) and the monitoring of NO2 and O2 in the inspirator lines of a patient undergoing nitric oxide therapy (iNO).
The NOxBOXi Nitric Oxide Delivery System includes:
· The NOxBOXi head unit, which delivers NO gas while in the intelligent delivery mode.
· Continuous monitoring and alarms for NO, O2, and NO2.
• The integrated NOxMixer which provides a backup NO delivery capability that is intended to deliver a continuous flow of NO, mixed with O2, for iNO therapy and provides a continuous treatment option during transit and transfer conditions within hospitals.
The NOxBOXi Nitric Oxide Delivery System must only be used in accordance with the indications, warnings and precautions described in the nitric oxide drug packaging (currently neonates). Refer to this material prior to use.
Product codes
MRN, MRQ, CCL, MRO, MRP
Device Description
The NOxBOXi Nitric Oxide Delivery System (NOxBOXi) simultaneously delivers Nitric Oxide (NO) medical gas, while monitoring Nitric Oxide, Nitrogen Dioxide (NO2), and Oxygen (O2) levels in the inspiratory limb of a ventilator for patients undergoing inhaled Nitric Oxide Therapy.
The system is designed for use by healthcare professionals to administer treatment to patients undergoing inhaled Nitric Oxide (iNO) therapy. The NOxBOXi will deliver nitric oxide in a synchronous manner to a single patient.
An integrated component to the NOxBOXi, the NOxMixer is intended to deliver a continuous flow of Nitric Oxide from the NOxBOXi, mixed in line with O₂ for use in iNO therapy. The NOxMixer will be used in conjunction with manually bagging a patient.
The NOxBOXi includes the NOxBOXi Head Unit, a NOxFLOW sample line, two NO feed hoses, two regulators (connector type dependent on the gas supplier), a test circuit, NO, O2, and NO2 monitors, power supply, drainage syringe, Operating Manual & Technical Guide.
This submission is for the introduction of new compatible ventilators including the addition of pediatric categories for existing ventilators, an additional optional software mode which disables the "Vent Flow Idle" alarm to reduce this alarm which may not be necessary and is considered a "nuisance" alarm in certain situations. Alarm initiations are still recorded in the log file. Additionally, language choices other than English have been disabled for this mode. There are no changes to the indications for use of the product, patient population of neonates, and there are no significant design changes.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
currently neonates
Intended User / Care Setting
healthcare professionals
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical performance data, usability testing. No clinical testing was required. Based on non-clinical data and testing conducted, it supports substantial equivalence and compatibility with additional ventilators. The device passed all testing and no different questions of safety or effectiveness were raised.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 868.5165 Nitric oxide administration apparatus.
(a)
Identification. The nitric oxide administration apparatus is a device used to add nitric oxide to gases that are to be breathed by a patient. The nitric oxide administration apparatus is to be used in conjunction with a ventilator or other breathing gas administration system.(b)
Classification. Class II. The special control for this device is FDA's “Guidance Document for Premarket Notification Submissions for Nitric Oxide Administration Apparatus, Nitric Oxide Analyzer, and Nitrogen Dioxide Analyzer.”
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health and Human Services logo on the left and the FDA text logo on the right. The FDA text logo is in blue and includes the acronym "FDA" followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in a stacked format.
May 23, 2024
Linde Gas & Equipment Inc. % Brittany Dunning Senior Quality & Regulatory Affairs Consultant Emergo Global Consulting, LLC 2500 Bee Cave Road, Building 1, Suite 300 Austin, Texas 78746
Re: K233251
Trade/Device Name: NOxBOXi Nitric Oxide Delivery System Regulation Number: 21 CFR 868.5165 Regulation Name: Nitric Oxide Administration Apparatus Regulatory Class: Class II Product Code: MRN, MRQ, CCL, MRO, MRP Dated: April 19, 2024 Received: April 19, 2024
Dear Brittany Dunning:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic.
2
See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Bradley Q. Quinn -S
Bradley Quinn Assistant Director DHT1C: Division of Sleep Disordered Breathing, Respiratory and Anesthesia Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
510(k) Number (if known) K233251
Device Name NOxBOXi Nitric Oxide Delivery System
Indications for Use (Describe)
NOxBOXi Nitric Oxide Delivery System is intended for use by healthcare professionals for the delivery and monitoring of a constant (user set) concentration of nitric oxide (NO) and the monitoring of NO2 and O2 in the inspirator lines of a patient undergoing nitric oxide therapy (iNO).
The NOxBOXi Nitric Oxide Delivery System includes:
· The NOxBOXi head unit, which delivers NO gas while in the intelligent delivery mode.
· Continuous monitoring and alarms for NO, O2, and NO2.
• The integrated NOxMixer which provides a backup NO delivery capability that is intended to deliver a continuous flow of NO, mixed with O2, for iNO therapy and provides a continuous treatment option during transit and transfer conditions within hospitals.
The NOxBOXi Nitric Oxide Delivery System must only be used in accordance with the indications, warnings and precautions described in the nitric oxide drug packaging (currently neonates). Refer to this material prior to use.
| Type of Use (Select one or both, as applicable) |
|---|
| X Prescription Use (Part 21 CFR 801 Subpart D) |
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
510(k) Summary
K233251
NOxBOXi Nitric Oxide Delivery System
1. Submission Sponsor
Linde Gas & Equipment Inc. (Linde) 208 W Main St., Livingston TN 38570, United States Contact: Dave Loflin Title: Director of Quality and FDA Regulations
2. Submission Correspondent
Emergo Global Consulting, LLC 2500 Bee Cave Road Building 1, Suite 300 Austin, TX 78746 Office Phone: (512) 327-9997 Email: LST.AUS.ProjectManagement@ul.com Contact: Brittany Dunning Title: Senior Consultant, Quality and Regulatory Affairs
3. Date Prepared
November 15, 2023
4. Device Identification
| Trade/Proprietary Name:
Classification Names:
Common/Usual Name: | NOxBOXi Nitric Oxide Delivery System
Nitric Oxide administration apparatus, back-up and gas analyzers
Nitric Oxide administration apparatus – primary
Nitric Oxide administration apparatus – backup
Nitric Oxide Analyzer
Nitrogen Dioxide Analyzer
Oxygen Gas Analyzer |
|------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Classification Regulation | 21 CFR 868.5165 – Nitric Oxide Administration Apparatus
21 CFR 868.2380 – Nitric Oxide Analyzer
21 CFR 868.2385 – Nitrogen Dioxide Analyzer
21 CFR 868.1720 – Oxygen Gas Analyzer |
| Product Code: | MRN |
| Additional procodes | MRO, MRP, MRQ, CCL |
| Device Class: | Class II |
| Classification Panel: | Anesthesiology |
5. Legally Marketed Predicate Device
Primary Predicate Device: NOxBOXi Nitric Oxide Delivery System K231823
5
Reference Device: NOxBOXi Nitric Oxide Delivery System K171696
6. Device Description
The NOxBOXi Nitric Oxide Delivery System (NOxBOXi) simultaneously delivers Nitric Oxide (NO) medical gas, while monitoring Nitric Oxide, Nitrogen Dioxide (NO2), and Oxygen (O2) levels in the inspiratory limb of a ventilator for patients undergoing inhaled Nitric Oxide Therapy.
The system is designed for use by healthcare professionals to administer treatment to patients undergoing inhaled Nitric Oxide (iNO) therapy. The NOxBOXi will deliver nitric oxide in a synchronous manner to a single patient.
An integrated component to the NOxBOXi, the NOxMixer is intended to deliver a continuous flow of Nitric Oxide from the NOxBOXi, mixed in line with O₂ for use in iNO therapy. The NOxMixer will be used in conjunction with manually bagging a patient.
The NOxBOXi includes the NOxBOXi Head Unit, a NOxFLOW sample line, two NO feed hoses, two regulators (connector type dependent on the gas supplier), a test circuit, NO, O2, and NO2 monitors, power supply, drainage syringe, Operating Manual & Technical Guide.
This submission is for the introduction of new compatible ventilators including the addition of pediatric categories for existing ventilators, an additional optional software mode which disables the "Vent Flow Idle" alarm to reduce this alarm which may not be necessary and is considered a "nuisance" alarm in certain situations. Alarm initiations are still recorded in the log file. Additionally, language choices other than English have been disabled for this mode. There are no changes to the indications for use of the product, patient population of neonates, and there are no significant design changes.
7. Indication for Use Statement
NOxBOXi Nitric Oxide Delivery System is intended for use by healthcare professionals for the delivery and monitoring of a constant (user set) concentration of nitric oxide (NO) and the monitoring of NO2 and O2 in the inspiratory ventilator lines of a patient undergoing nitric oxide therapy (iNO).
The NOxBOXi Nitric Oxide Delivery System includes:
- The NOxBOXi head unit, which delivers NO gas while in the intelligent delivery mode.
- · Continuous monitoring and alarms for NO, O2, and NO2.
- The integrated NOxMixer which provides a backup NO delivery capability that is intended to deliver a continuous flow of NO, mixed with O₂, for iNO therapy and provides a continuous treatment option during transit and transfer conditions within hospitals.
The NOxBOXi Nitric Oxide Delivery System must only be used in accordance with the indications, contraindications, warnings and precautions described in the nitric oxide drug packaging inserts and labeling (currently neonates). Refer to this material prior to use.
6
8. Substantial Equivalence Discussion
The following table compares the NOxBOXi to the predicate device with respect to intended use, technological characteristics and principles of operation.
| | Subject: NOxBOXi Nitric Oxide
Delivery System | Predicate: NOxBOXi Nitric Oxide
Delivery System | Comparison |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| 510(k) Number | K233251 | K231823 | N/A |
| Manufacturer | NOXBOX Ltd. | NOXBOX Ltd. | No Change |
| | Regulatory & Indications for Use | | |
| Product Code | MRN, MRO, MRP, MRQ, CCL | | No Change |
| Regulation Numbers | 21 CFR 868.5165, .2380, .2385, .1720 | | No Change |
| Regulation Name | Nitric Oxide administration apparatus, back-up and gas analyzers | | No Change |
| Indications for Use | NOXBOXI Nitric Oxide Delivery System is intended for use by healthcare
professionals for the delivery and monitoring of a constant (user set)
concentration of nitric oxide (NO) and the monitoring of NO2 and O2 in the
inspiratory ventilator lines of a patient undergoing nitric oxide therapy (iNO).
The NOxBOXi Nitric Oxide Delivery System includes:
The NOxBOXi head unit, which delivers NO gas while in the intelligent delivery mode. Continuous monitoring and alarms for NO, O2 and NO2. The integrated NOxMixer which provides a backup NO delivery capability that is intended to deliver a continuous flow of NO, mixed with O2, for iNO therapy and provides a continuous treatment option during transit and transfer conditions within hospitals. The NOxBOXi Nitric Oxide Delivery System must only be used in accordance
with the indications, contraindications, warnings and precautions described
in the nitric oxide drug packaging inserts and labeling (currently neonates).
Refer to this material prior to use. | | No Change |
| Technical | | | |
| NO administration | NO blended with O2 in the patient's inhalation circuit | | No Change |
| NO flow rate (sample flow
rate) | 225 ml/min | | No Change |
| NO concentration
provided | 0.0 TO 80ppm | | No Change |
| NO monitor | Yes | | No Change |
| O2 monitor | Yes | | No Change |
| Monitoring accuracy | NO & NO2 - +/- 2% or 0.2ppm | | No Change |
| NO2 monitor & alarm | Yes | | No Change |
| Battery Backup capability | 4 hours without AC power | | No Change |
| Manual bagging & back
up system | NOXMIXER® | | No Change |
| NO dosing range in
manual mode | 0 - 185ppm on 800ppm cylinders | | No Change |
| | Subject: NOxBOXi Nitric Oxide
Delivery System | Predicate: NOxBOXi Nitric Oxide
Delivery System | Comparison |
| NO dosing Accuracy in
manual mode | $ \pm 20% or 2 ppm, whichever is the greater for NO doses from 5 - 80 ppm (800 ppm drug cylinder) and O2 flow rates of 5 - 14 L/min * +/-40% or 4 ppm, whichever is the greater; for NO doses from 0 to 80 to 185 ppm (800 ppm drug cylinder) and O2 flow rates of 2 to 14 to 25 L/min $ | | No Change |
| NO flow in manual mode | Adjustable 50 – 600 mL/min of NO/N2 | | No Change |
| O2 flow range in manual
bagging mode | 2 to 25 L/min of O2 | | No Change |
| Oxygen inlet pressure | 3.5 – 4.5 bar | | No Change |
| NO delivery pressure | 1.65 bar from manual control valve | | No Change |
| Manual bagging & back
up system | NOxMIXER® | | No Change |
| Dimensions | 65 mm (W) X 185 mm (H) x 60.8 mm (D) | | No Change |
| Pre-use set up time | Instant set-up | | No Change |
| Monitoring during manual
bagging | Yes | | No Change |
| Alarms active during
bagging | Yes | | No Change |
| Stand alone vs Built-in | Built-in | | No Change |
| Can be used as a back-up
function | Yes | | No Change |
| Back-up accuracy | $ \pm 20% or 2 ppm, whichever is the greater for NO doses from 5 - 80 ppm (800 ppm drug cylinder), * +/-40% or 4 ppm, whichever is the greater; for NO doses from 0 to 80 to 185 ppm (800 ppm drug cylinder) $ | | No Change |
| | Ventilator Compatibility | | |
| Compatible Ventilators | Various models from the following
manufacturers:
Bio-Med Devices Bunnell Carefusion Carefusion / SensorMedics Drägerwerk Fisher & Paykel Healthcare General Electric Hamilton Medical IMT Medical (Vyaire) Maquet (Getinge) Newport (Covidien) Nihon Kohden Percussionaire (Sentec) Philips Respironics Puritan Bennett (Covidien) Smiths Medical Vapotherm Zoll | Various models from the following
manufacturers:
Bio-Med Devices Bunnell Carefusion Carefusion / SensorMedics Drägerwerk Fisher & Paykel Healthcare General Electric Hamilton Medical IMT Medical (Vyaire) Maquet (Getinge) Newport (Covidien) Nihon Kohden Percussionaire (Sentec) Philips Respironics Puritan Bennett (Covidien) Smiths Medical Vapotherm N/A | Equivalent;
testing
shows no
new
questions
raised
regarding
safety and
effectiveness |
Comparison of Characteristics With Changes From Device Cleared in K23182320898
7
8
9. Non-Clinical and Usability Performance Data
NOxBOXi has been verified and validated to ensure that it meets its functional, performance, and usability specifications and requirements. The device has been tested in compliance to international standards and US FDA guidance documents including the following:
- . FDA guidance "Use of International Standard ISO 10993-1, "Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process" (K171696)
- . FDA guidance "Premarket Notification Submissions for Nitric Oxide Delivery Apparatus, Nitric Oxide Analyzer and Nitrogen Dioxide Analyzer" including accuracy of NO delivery, response of NO delivery to external perturbations and user changes, purity of NO drug delivery, acceptable / minimal production of NO2, NO analyzer accuracy, NO2 analyzer accuracy, and compatibility testing of ventilators listed in the product labeling FDA guidance "Content of Premarket Submissions for Software Contained in Medical Devices" (K171696)
- . FDA guidance "Applying Human Factors and Usability Engineering to Medical Devices." (K171696)
- ISO 14971: Medical Devices Application of Risk Management to Medical Devices ●
- . ISO 10993-1: Biological Evaluation of Medical Devices Part 1: Evaluation and Testing Within a Risk Management Process (K171696)
- . ISO 10993-5: Biological Evaluation of Medical Devices Part 5: Tests for In Vitro Cytotoxicity (K171696)
- . ISO 10993-10: Biological Evaluation of Medical Devices Part 10: Tests for Irritation and Skin Sensitization (K171696)
- IEC 60601-1: Medical Electrical Equipment – Part 1: General Requirements for Basic Safety and Essential Performance (K171696)
- . IEC 60601-1-2: Medical Electrical Equipment – Part 1-2: General Requirements for Basic Safety and Essential Performance - Collateral Standard: Electromagnetic Disturbances -Requirements and Tests (K171696)
- IEC 62366: Medical Devices – Application of Usability Engineering to Medical Devices (K171696)
- ISO 80601-2-55: Medical Electrical Equipment – Part 2-55: Particular Requirements for the Basic Safety and Essential Performance of Respiratory Gas Monitors (K171696)
- IEC 62304: Medical Device Software – Software Life Cycle Processes (K171696)
- . ISO 15223-1: Medical Devices – Symbols to be Used With Medical Device Labels, Labelling, and Information to be Supplied – Part 1: General Requirements
Additionally, gases delivered through the NOxBOXi system were analyzed for the presence of volatile organic compounds (VOC) and particulate matter. Measurement of the resulting VOC concentrations resulted in levels that were three orders of magnitude below OSHA permissible exposure levels. Particulate testing determined that the gas delivered by the NOxBOXi system contained particulate levels well below the EPA's maximum limits for total suspended particulates.
Testing for this submission was limited to the aspects that could be affected by including compatibility with additional ventilators and ventilator categories, as well as the addition of
9
an optional software mode. Usability testing was conducted for this submission in relation to the software change. No clinical testing was required to support substantial equivalency of this medical device.
10. Conclusions/Statement of Substantial Equivalence
This submission is for the addition of compatibility claims for specific ventilators and for the ventilators previously cleared for pediatric population, as well as the addition of an optional software mode. This submission is not related to product changes. There are no changes to the indications for use of the product or the patient population of neonates. The abovedescribed non-clinical data support the substantial equivalence of the device and the compatibility with additional ventilators. The NOxBOXi passed all testing and no different questions of safety or effectiveness were raised. The information provided within this premarket notification supports substantial equivalence to the predicate device.